Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Novavax Inc (NVAX) Price & Performance

Invesco DB Commodity Index Tracking FundTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Commodity Index Tracking Fund vs Novavax Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.63, while Novavax Inc trades at $8.45 (market cap $1.38B). The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

DBCNVAX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$31.69$11.19
52-Week Low
$21.62$6.22
Market Cap
$1.38B
Enterprise Value
$889.29M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Commodity Index Tracking Fund

DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.

Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.

Novavax Inc

Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.

The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.

Returns comparison

Trailing returns across standard periods

About Invesco DB Commodity Index Tracking Fund

DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.

Read more on DBC

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX